Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its price target decreased by investment analysts at Morgan Stanley from $146.00 to $136.00 in a report released on Thursday, November 2nd. The firm currently has an “overweight” rating on the medical equipment provider’s stock. Morgan Stanley’s target price would indicate a potential upside of 21.20% from the company’s previous close.
A number of other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. BMO Capital Markets dropped their price target on shares of Zimmer Biomet Holdings from $140.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday, November 2nd. Oppenheimer Holdings, Inc. set a $137.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Monday, August 14th. Canaccord Genuity restated a “buy” rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $153.00 target price on shares of Zimmer Biomet Holdings in a report on Wednesday, July 12th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet Holdings has an average rating of “Hold” and a consensus target price of $133.71.
Shares of Zimmer Biomet Holdings (NYSE ZBH) opened at $112.21 on Thursday. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88. The company has a market cap of $22,720.00, a P/E ratio of 13.76, a P/E/G ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings has a one year low of $98.20 and a one year high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same period in the prior year, the business earned $1.79 earnings per share. The company’s revenue for the quarter was down .8% on a year-over-year basis. equities analysts predict that Zimmer Biomet Holdings will post 8.03 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/zimmer-biomet-holdings-inc-zbh-pt-lowered-to-136-00/1751106.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of Zimmer Biomet Holdings by 4.1% during the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock valued at $2,236,657,000 after purchasing an additional 679,080 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Zimmer Biomet Holdings by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock worth $1,718,057,000 after purchasing an additional 339,106 shares during the period. State Street Corp boosted its holdings in shares of Zimmer Biomet Holdings by 2.4% in the 1st quarter. State Street Corp now owns 8,193,165 shares of the medical equipment provider’s stock worth $1,000,463,000 after purchasing an additional 191,747 shares during the period. Longview Partners Guernsey LTD boosted its holdings in shares of Zimmer Biomet Holdings by 17.7% in the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares during the period. Finally, Nordea Investment Management AB lifted its stake in shares of Zimmer Biomet Holdings by 7.3% during the 3rd quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock worth $617,961,000 after acquiring an additional 357,302 shares during the last quarter. 85.44% of the stock is currently owned by hedge funds and other institutional investors.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.